Scarica l'app Stockscreener
2.10
9.87%
-0.23
Terns Pharmaceuticals Inc Borsa (TERN) Ultime notizie
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN) - Yahoo Finance
Terns pharmaceuticals chief medical officer sells $2,365 in stock - Investing.com Australia
Terns Pharmaceuticals Reports Inducement Grant To New Employees Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Terns Pharmaceuticals stock hits 52-week low at $2.5 By Investing.com - Investing.com South Africa
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Terns Pharmaceuticals Attracts Top Talent with 611,000-Share Equity Package - Stock Titan
Terns Pharmaceuticals stock hits 52-week low at $2.5 - Investing.com India
Terns Pharmaceuticals stock hits 52-week low at $4.16 - MSN
Insider Purchases Worth US$5.17m See Losses As Terns Pharmaceuticals Market Value Drops To US$255m - simplywall.st
HighTower Advisors LLC Invests $468,000 in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Charles Schwab Investment Management Inc. Raises Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives $18.30 Average Price Target from Analysts - Defense World
Terns Pharmaceuticals Reports 2024 Progress and Outlook - TipRanks
Terns Pharmaceuticals stock hits 52-week low at $3.08 By Investing.com - Investing.com South Africa
All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy - MSN
Terns Pharmaceuticals stock hits 52-week low at $3.08 - Investing.com
Bank of New York Mellon Corp Raises Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals (NASDAQ:TERN) Earns Market Perform Rating from William Blair - Defense World
Terns Pharmaceuticals Inc. (TERN) reports earnings - Quartz
Terns Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Terns Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - GlobeNewswire
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential By Investing.com - Investing.com South Africa
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential - Investing.com
Terns Pharmaceuticals stock hits 52-week low at $3.27 By Investing.com - Investing.com Australia
Terns Pharmaceuticals stock hits 52-week low at $3.27 - Investing.com India
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street - sharewise
Rhumbline Advisers Acquires 13,479 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
3 Growth Stocks with Exciting Potential - The Globe and Mail
Chronic Myeloid Leukemia Market Expected to Experience Major - openPR
Public market insider buying at Paramount Resources (POU) - The Globe and Mail
Terns Pharmaceuticals (TERN) Projected to Post Quarterly Earnings on Thursday - Defense World
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of “Moderate Buy” from Brokerages - The AM Reporter
Terns Pharmaceuticals stock hits 52-week low at $3.54 - Investing.com India
Terns Pharmaceuticals stock hits 52-week low at $3.54 By Investing.com - Investing.com South Africa
Brokerages Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Target Price at $18.30 - Defense World
William Blair Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
William Blair Initiates Terns Pharmaceuticals at Market Perform -February 28, 2025 at 08:12 am EST - Marketscreener.com
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Terns Pharmaceuticals reports progress in clinical trials By Investing.com - Investing.com Australia
New Terns Pharmaceuticals CFO Receives $2.8M Stock Option Package: What's Behind the Compensation? - StockTitan
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):